Investigating the Efficacy of a Paediatric Fertility Preservation Decision Aid in Parents and Adolescents and Young Adults (CAYA) Cancer Survivors
Launched by MURDOCH CHILDRENS RESEARCH INSTITUTE · Mar 19, 2025
Trial Information
Current as of April 30, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a special tool designed to help parents and young adults who have survived cancer understand their options for preserving fertility, which is the ability to have children in the future. Sometimes, when patients go through cancer treatment, they may lose the ability to have children later in life. This trial aims to see if using a fertility preservation decision aid (FP DA), along with regular information from healthcare providers, can better meet the needs of parents and young cancer survivors when it comes to making decisions about fertility.
To be eligible for this study, parents must be guardians of cancer survivors who were 25 years old or younger when diagnosed and have completed their cancer treatment. Young adults aged 16 and older who have survived cancer and are no longer receiving treatment can also join. Participants will receive information and support to help them understand their fertility options better. It's important to note that the study is not yet recruiting participants, and some individuals currently undergoing treatment or in palliative care, as well as certain minors, will not be eligible to participate. This trial could be a valuable opportunity for families to gain clarity about fertility options after cancer treatment.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Inclusion Criteria for both parents and survivors:
- • Be able to communicate in English.
- • Signed written informed consent form.
- Inclusion Criteria for parents only:
- • • Parents/guardians of CAYA survivors who were ≤25 years (2) when diagnosed with cancer and have completed curative gonadotoxic treatment
- • Inclusion Criteria for survivors only
- • CAYA cancer survivors aged 16 years or over who have completed curative gonadotoxic treatment.
- • Participants can be on long-term adjuvant or endocrine therapy.
- • Participants may have achieved a pregnancy or livebirth.
- Exclusion Criteria:
- Exclusion Criteria for both parents and survivors:
- • CAYA patients currently undergoing cancer treatment and their parents/guardians.
- • CAYA patients who are palliative and their parents/guardians
- • A family member already in the study.
- Exclusion Criteria for survivors only:
- • • Minors who are not deemed to be mature minors as per protocol
About Murdoch Childrens Research Institute
Murdoch Children's Research Institute (MCRI) is a leading pediatric research organization based in Australia, dedicated to improving child health through innovative research and clinical trials. With a focus on understanding and addressing the unique health challenges faced by children, MCRI collaborates with hospitals, universities, and community partners to translate research findings into practical solutions. The institute's multidisciplinary team of scientists, clinicians, and researchers is committed to advancing pediatric medicine and enhancing the quality of life for children and their families through groundbreaking studies and evidence-based interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Melbourne, Victoria, Australia
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported